Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
about
Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysisAdherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare populationLong-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study.Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research DatabaseAdherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study.Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.Real-world clinical and economic outcomes for daily teriparatide patients in Japan.The impact of teriparatide adherence and persistence on fracture outcomes.Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.Is two better than one? Combining antiresorptive and anabolic osteoporosis medications.Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
P2860
Q34529920-D4061EA9-0C74-4968-B4FC-7BD675598692Q35092617-C182208A-9D74-4CBF-B76F-1EE5AF3B1ED8Q35968876-63AA5E3F-62B5-41CA-8FAA-CA57894830ADQ36873339-3B068825-D57F-4312-8C56-85F03476A95DQ37008062-9CEA433B-723C-4827-91BD-FF2D518678BEQ37168515-B9DFA5A2-0077-4544-B563-D6C2D918690CQ37422363-C55760EE-6807-4274-89F1-42FC4C25886BQ37639393-1BD2890E-4153-4788-A6D6-70B496327A79Q38241347-EB9E4DEE-B9F9-41CD-9E4C-40F0AA1D1D08Q39204185-9FD408F8-E260-4EBB-9628-BD7E13FD61F5Q40506119-A96F9A5E-CD95-4D4F-8916-C28CCABF9C30Q43607111-AA91D453-A539-48A7-9291-68CC3FA1F517Q44042465-3BC49C4C-F329-4A70-B6FF-67EAB32CD1B6Q45251972-E8FF2728-254E-4318-A564-C971DB7100A5Q50568548-BB309781-1373-4401-8A50-A62D5D56F82C
P2860
Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Adherence and persistence with ...... icare, and Medicaid insurance.
@en
Adherence and persistence with ...... icare, and Medicaid insurance.
@nl
type
label
Adherence and persistence with ...... icare, and Medicaid insurance.
@en
Adherence and persistence with ...... icare, and Medicaid insurance.
@nl
prefLabel
Adherence and persistence with ...... icare, and Medicaid insurance.
@en
Adherence and persistence with ...... icare, and Medicaid insurance.
@nl
P2093
P2860
P1476
Adherence and persistence with ...... icare, and Medicaid insurance.
@en
P2093
E S Meadows
J A Johnston
S A Foster
P2860
P2888
P304
P356
10.1007/S00198-010-1297-Z
P407
P577
2010-08-27T00:00:00Z
P6179
1019074710